Absci (NASDAQ:ABSI) Releases Earnings Results, Beats Expectations By $0.01 EPS

Absci (NASDAQ:ABSI) issued its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01, FiscalAI reports. Absci had a negative net margin of 4,113.68% and a negative return on equity of 62.33%. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $1.39 million.

Here are the key takeaways from Absci’s conference call:

• ABS-201 is on track—blinded safety/tolerability/PK data from the SAD cohorts is expected next month, with an interim 13‑week proof‑of‑concept readout in H2 2026 and a full 26‑week POC in early 2027, and PK modeling supports roughly 2–3 injections over six months.
• Management projects a >$25 billion U.S. total available market for androgenetic alopecia and cites a target profile (~35 hairs/cm² similar to high‑dose oral minoxidil) that could expand the market, but these figures are forward‑looking and survey‑based.
• The pipeline is expanding within prolactin biology with the addition of ABS-202, an anti‑prolactin receptor antibody aimed at inflammatory/immune indications, signaling strategic focus on a franchise approach beyond AGA and endometriosis.
• Absci is de‑emphasizing oncology and will stop internal funding for ABS‑301 and ABS‑501, narrowing therapeutic diversity and concentrating resources on ABS‑201 and prolactin‑focused programs.
• Financials show $125.7M in cash and marketable securities at March 31, 2026 with management saying runway into H1 2028, Q1 R&D spend rose to $19.3M, and the company is pursuing non‑dilutive partnerships and AI‑driven efficiency gains.

Absci Stock Performance

Shares of ABSI stock opened at $5.75 on Friday. Absci has a fifty-two week low of $2.24 and a fifty-two week high of $6.24. The stock has a market capitalization of $893.84 million, a P/E ratio of -6.76 and a beta of 2.36. The company has a 50 day moving average price of $3.29 and a 200 day moving average price of $3.31.

Insider Transactions at Absci

In related news, insider Andreas Busch purchased 100,000 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were bought at an average price of $2.29 per share, for a total transaction of $229,000.00. Following the acquisition, the insider directly owned 421,446 shares in the company, valued at $965,111.34. This trade represents a 31.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 10.49% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ABSI. Creative Planning boosted its stake in Absci by 145.4% during the 2nd quarter. Creative Planning now owns 46,882 shares of the company’s stock worth $120,000 after purchasing an additional 27,775 shares during the period. Jain Global LLC purchased a new stake in Absci in the 3rd quarter valued at approximately $104,000. The Manufacturers Life Insurance Company grew its holdings in Absci by 35.8% during the second quarter. The Manufacturers Life Insurance Company now owns 40,175 shares of the company’s stock worth $103,000 after acquiring an additional 10,585 shares during the period. Abel Hall LLC purchased a new stake in shares of Absci during the 4th quarter worth $54,000. Finally, Commonwealth Equity Services LLC acquired a new position in Absci during the fourth quarter worth about $50,000. Institutional investors and hedge funds own 52.05% of the company’s stock.

Analyst Ratings Changes

ABSI has been the subject of a number of recent analyst reports. Morgan Stanley cut shares of Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target for the company. in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Absci in a report on Monday, April 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Absci in a report on Wednesday, March 25th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.44.

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.